Loading
This study tests a PARP inhibitor; the registry reports that it is active not recruiting.
The registry lists NCT02264678 as active not recruiting, last updated 2026-07-24. Enrolment is 358 actual participants. Interventions: Administration of ceralasertib, Administration of ceralasertib in combination with olaparib, Administation of ceralasertib in combination with durvalumab, Administration of ceralasertib monotherapy, Administration of ceralasertib and olaparib, Administration of ceralasertib and durvalumab, Administration of ceralasertib in combination with AZD5305, Administration of ceralasertib in combination with carboplatin. Primary measures include The number of subjects with adverse events/serious adverse events; Module 4 only: Effect of food on ceralasertib absorption by Intensive PK assessments after a single oral dose of ceralasertib (Part A). No results are posted in the registry; this does not exclude separate publications.
Shares Saruparib, PARP, Ovarian cancer.
Shares Saruparib, PARP, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/